Literature DB >> 10220571

ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P.

Z S Chen1, T Furukawa, T Sumizawa, K Ono, K Ueda, K Seto, S I Akiyama.   

Abstract

Non-P-glycoprotein-mediated multidrug-resistant C-A120 cells that overexpressed multidrug resistance protein (MRP) were 10.8- and 29. 6-fold more resistant to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) and SN-38, respectively, than parental KB-3-1 cells. To see whether MRP is involved in CPT-11 and SN-38 resistance, MRP cDNA was transfected into KB-3-1 cells. The transfectant, KB/MRP, which overexpressed MRP, was resistant to both CPT-11 and SN-38. 2-[4-Diphenylmethyl)-1-piperazinyl]ethyl-5-(trans-4,6-dimethyl-1,3 , 2-dioxaphosphorinan-2-yl)-2, 6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate P-oxide (PAK-104P) and MK571, which reversed drug resistance in MRP overexpressing multidrug-resistant cells, significantly increased the sensitivity of C-A120 and KB/MRP cells, but not of KB-3-1 cells, to CPT-11 and SN-38. The accumulation of both CPT-11 and SN-38 in C-A120 and KB/MRP cells was lower than that in KB-3-1 cells. The treatment with 10 microM PAK-104P increased the accumulation of CPT-11 and SN-38 in C-A120 and KB/MRP cells to a level similar to that found in KB-3-1 cells. The ATP-dependent efflux of CPT-11 and SN-38 from C-A120 and KB/MRP cells was inhibited by PAK-104P. DNA topoisomerase I expression, activity, and sensitivity to SN-38 were similar in the three cell lines. Furthermore, the conversion of CPT-11 to SN-38 in KB-3-1 and C-A120 cell lines was similar. These findings suggest that MRP transports CPT-11 and SN-38 and is involved in resistance to CPT-11 and SN-38 and that PAK-104P reverses the resistance to CPT-11 and SN-38 in tumors that overexpress MRP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10220571

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  22 in total

1.  ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.

Authors:  M Li; E L Seiser; R M Baldwin; J Ramirez; M J Ratain; F Innocenti; D L Kroetz
Journal:  Pharmacogenomics J       Date:  2016-11-15       Impact factor: 3.550

Review 2.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.

Authors:  Qingyu Zhou; Alex Sparreboom; Eng-Huat Tan; Yin-Bun Cheung; Ann Lee; Donald Poon; Edmund J D Lee; Balram Chowbay
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

4.  Dual-acting histone deacetylase-topoisomerase I inhibitors.

Authors:  William Guerrant; Vishal Patil; Joshua C Canzoneri; Li-Pan Yao; Rebecca Hood; Adegboyega K Oyelere
Journal:  Bioorg Med Chem Lett       Date:  2013-04-04       Impact factor: 2.823

Review 5.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

6.  Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.

Authors:  Zhiyong Liao; Robert W Robey; Josée Guirouilh-Barbat; Kenneth K W To; Orsolya Polgar; Susan E Bates; Yves Pommier
Journal:  Mol Pharmacol       Date:  2007-11-05       Impact factor: 4.436

7.  Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.

Authors:  Upal Roy; Geetika Chakravarty; Kerstin Honer Zu Bentrup; Debasis Mondal
Journal:  Biol Pharm Bull       Date:  2009-12       Impact factor: 2.233

8.  Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer.

Authors:  M Fakih; R Wong
Journal:  Curr Oncol       Date:  2010-07       Impact factor: 3.677

9.  Involvement of multidrug resistance-associated protein 1 in intestinal toxicity of methotrexate.

Authors:  Sayaka Kato; Katsuaki Ito; Yukio Kato; Tomohiko Wakayama; Yoshiyuki Kubo; Shoichi Iseki; Akira Tsuji
Journal:  Pharm Res       Date:  2009-03-14       Impact factor: 4.200

10.  Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.

Authors:  S-J Lee; M Gounder; E H Rubin; Jong Ming Li; Zheming Gu; A Thalasila; E Loyer; A P Kudelka; C F Verschraegen
Journal:  Invest New Drugs       Date:  2008-07-04       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.